Tessara Therapeutics – Alzheimer’s Disease Organoids

The Alzheimer’s Disease Organoids Poster from Axol Bioscience and Tessara Therapeutics presents a cutting-edge approach to modeling neurodegeneration using iPSC-derived 3D brain micro-tissues. These RealBrain® organoids offer a physiologically relevant, scalable, and ethically sourced alternative to traditional models for drug discovery and personalized medicine.

Key highlights include:

• RealBrain® 3D Micro-Tissues: Rapidly maturing, optically clear, and compatible with high-throughput assays; produced at scale (>15,000/day) using robotic manufacturing.
• ADBrain™ Model: Mimics Alzheimer’s pathology including Aβ42 deposition, Tau hyperphosphorylation, neural network loss, and ferroptosis susceptibility.
• Ferroptosis Assays: Demonstrated increased cell death in ADBrain™ vs. healthy controls using RSL3, Liproxstatin-1, and Ferrostatin-1.
• Axol iPSC-Derived Neural Stem Cells: Differentiated into neurons and glia, used to generate both healthy and AD patient-derived micro-tissues, including PS1 mutation lines.
• Patient-Derived Models: Show reduced network connectivity and cell density, enabling “clinical trial in a dish” applications.
• Validated Endpoints: Cell viability, LDH release, Tau quantification, and Aβ42 localization.

This collaboration paves the way for non-animal-based screening approaches and accelerates personalized neurology research.

Featured Axol Products:

• axoCells™ Neural Stem Cells (NSCs) – iPSC-derived NSCs for 3D brain tissue generation
• axoCells™ Media & Supplements – ISO9001-accredited reagents for neural differentiation and maintenance
• Custom iPSC Lines – Including familial Alzheimer’s disease donors (e.g., PS1 mutation)